Comparision of efficacy of salmeterol or fluticazone propionate monotherapy and combination of these drugs in atopic bronchial asthma

The open study has been carried out in 35 mild to moderate atopic bronchial asthma (ABA) patients in order to investigate efficacy, safety and anti-inflammatory activity of the long-acting beta-2-agonist salmeterol (S), the inhaled glucocorticosteroid fluticazone propionate (FP) and their combination.
The efficacy of the drugs was evaluated based on the results of the patients’ clinical and functional examination including peak flow rate measurement, lung function testing, dynamics of asthmatic symptoms and frequency of beta-2-agonists usage after 12-week treatment.
The anti-inflammatory activity was assessed according to the dynamics of the inflammatory biomarkers which Э are the eosinophylic cationic protein (ECP) blood plasma level and metacholine-induced bronchial hyperreactivity (BH).
We observed a reduction in asthma symptoms (score number was diminished by 73%, p < 0.05), an increase in lung function parameters (FEVi was increased by 9.7%, p<0.05; PEF was increased by 13.3%), a reduction in beta-2-agonists need by 82% (p<0.05), a slackening of metacholine-induced bronchial hyperreactivity (metacholine concentration caused FEV₁ drop by 20% (MC20) was increased in 1.8 times, p>0.05); and a decrease in ECP level by 4.5 mcg/l (p>0.05) after 12-week therapy of the mild atopic asthmatic patients with measured aerosol inhaler Serevent in a dose of 50 meg twice a day.
Fluxotide measured aerosol inhaler course treatment in a dose of 250 meg twice a day in the atopic moderate t asthmatic patients led to the asthma symptoms reduction by 98% (p<0.05), the increase in lung function parameters (by 20.6% for FEV₁ and 28% for PEF, p<0.05), the reduction in beta-2-agonists need by 94% (p<0.05), the metacholine-induced bronchial hyperreactivity slackening (MC20 was increased in 3.5 times, p<0.05) and the ECP level decreasing by 19% (p<0.05).
The combined therapy with 250 meg of FP and 50 meg of Serevent twice a day during 12 weeks influenced more intensively in moderate atopic asthmatic patients that was expressed in the asthma symptoms reduction by 99% (p<0.05), the increase in lung function parameters (by 27% for FEV₁ and 27.4% for PEF, p<0.05), the reduction in beta-2-agonists need by 99.7% (p<0.05) and a stronger effect to allergic inflammation which was shown in the metacholine-induced bronchial hyperreactivity slackening in 4 times (p<0.05) and the ECP level lowering by 54% (p<0.05).

1. Айсанов З.Р., Стулова О.Ю., Калманова Е.Н. и др. Оценка эффективности комбинированной терапии фликсотидом и серевентом у больных бронхиальной астмой / / Пульмонология.— 1998.— N° 3.— С.14—18.

2. Бронхиальная астма. Глобальная стратегия / / Там же.— 1996.— Прил.— С.1 — 165.

3. Официальный бюллетень Европейского респираторного общества. Восприимчивость дыхательных путей / / Там же.— 1993.— Прил.— С.60—86.

4. Сепиашвили Р.И., Мачарадзе Д.Ш., Балаболкин И.И. и др. Серевент и фликсотид: высокая терапевтическая эффективность их комбинации при бронхиальной астме у детей / / Интерн, журн. иммунореабил.— 1997.— № 7.— С.63—66.

5. Суточникова О.А. Ингаляционные глюкокортикостероиды — наиболее эффективные и безопасные противовоспалительные препараты для лечения астмы / / Рус. мед. журн. Спец. вып.: Пульмонология.— 1997.— Т.5, N° 17.— С.1115—1121.

6. ЦойА.Н. Клиническая фармакология ингаляционных глюкокортикостероидов. / / Пульмонология.— 1996.— № 2.— С.85—90

7. Чучалин А.Г., Соколов А.С., Пашкова Т.П. и др. Опыт применения пролонгированного Рг-симпатомиметика сальметерола у больных бронхиальной астмой / / Там же.— С.79—83.

8. Чучалин А.Г., Черняк Б.А., Медникова О.Б., Беда М.В. Эффективность сочетанного применения флютиказона пропионата и сальметерола при 18-месячной терапии больных стероидозависимой бронхиальной астмой / / Там же.— 1998.— № 3.— С.64—70.

9. Barnes P.J. New concepts' in the pathogenesis of bronchial responsiveness and asthma / / J.Allergy clin. Immunol.— 1989.— Vol. 83, N° 6.— P.1013—1026.

10. D’Alonzo G.E. Эффективность ингаляционного сальметерола в лечении астмы / / Клин, фармакол. и тер.— 1996.— № 5 (4).— С.56—60.

11. Greening А .P., Ind P.W., Northfied М., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid / / Lancet.— 1994.— Vol.344, N° 8917.— P.219—224.

12. Kumar J., Mohan A., Sharma S.K., Pande J.N. Recent concepts in the pathogenesis of bronchial asthma / / Indian J. Chest Dis. allied Sci.— 1997.— Vol.39, N° 1.— P.27— 45; Информ. сборник РААКИ.— 1997.— N° 9.— С.1—2.

13. Sterk P.J., Fabbri L..M., Quanjer P.H. et al. Airway responsiveness / / Eur. Respir. J.— 1993.— Vol.6.— Suppl. 16.— P.53—83.

14. Verberne A., Frost C., Duiverman E. et al. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma / / Amer. J. Respir. Crit. Care M ed.— 1998.— Vol.158, № 1.- P .213-219.